Final NHS nod for Roche’s RoActemra
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
Read More
Tag: giant cell arteritis
NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
Read More
NHS use of Roche’s Roactemra turned down for giant cell arteritis
It is looking unlikely that patients with giant cell arteritis will get NHS access to Roche’s Roactemra, after the drug was turned down by cost regulators in draft guidelines.
Read More
US approves first drug for giant cell arteritis
Roche’s Actemra has become the first drug approved by US regulators specifically to treat giant cell arteritis, a form of vasculitis that results in inflammation of blood vessels.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
